Long-Term Complete Remission of a Patient With Double-Hit Diffuse Large B-Cell Lymphoma Treated by Chemoimmunotherapy and Chinese Herbal Medicine

被引:2
|
作者
Liang, Henry [1 ,4 ]
Guo, Jessica [2 ]
Li, Chun Guang [3 ]
机构
[1] Western Sydney Univ, Campbelltown Campus, Artarmon, NSW, Australia
[2] Dr Henry Liang Clin, Artarmon, NSW, Australia
[3] Western Sydney Univ, NICM Hlth Res Inst, Penrith, NSW, Australia
[4] Dr Henry Liang Clin, Level 1, 66 Hampden Rd, Artarmon, NSW 2064, Australia
关键词
diffuse large B-cell lymphoma; double-hit lymphoma; complete remission; long term survival; Chinese herbal medicine; MULTICENTER;
D O I
10.1177/15347354221147515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Double-hit diffuse large B-cell lymphoma (DHL) is an uncommon subtype of lymphoma which poorly responds to current drug therapies and has low rates of long-term survival in the patients. Herein, we report a case of a 73-year-old Caucasian male who was diagnosed with DHL with double-hit mutations of rearrangement of both c-MYC and BCL2 in November 2013. He commenced the standard R-CHOP-14 chemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone) but changed to dose-adjusted DA-EPOCH-R protocol (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and rituximab) in the second and third cycles due to double-hit mutation. Because of intolerance to the intensive therapy, the patient decided to switch to Chinese medicine intervention. From March 2014 to December 2019, he was prescribed with a classical Chinese herbal formula-Sijunzi Decoction plus Prunella vulgaris based prescriptions. After 2 months of the Chinese herbal medicine intervention, the patient felt his right groin mass disappeared. Imaging follow-up showed no residual masses, and no lymphadenopathy was seen. During the period of Chinese herbal medicine treatment, his adherence and tolerability were well maintained with no adverse events. Imaging surveillances afterward found no evidence of lymphoma recurrence. His regular blood tests indicated that the patient's blood counts were normal and stable; no hematologic toxicity, hepatoxicity, or nephrotoxicity associated with Chinese herbal medicine were found. Follow-up visits until 2020 found that he had been living and enjoying a good quality of life for over 8 years post-diagnosis. This case study illustrates the potential values of Chinese herbal medicine in DHL treatment, alongside chemo-immunotherapy, and in maintaining long-term survival and satisfactory quality of life for DHL patients. The case report provides clinicians with preliminary evidence of the use of Chinese herbal medicine as a therapeutic strategy in the management of DHL.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors
    Morton, Lindsay M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) : 1648 - +
  • [42] Long-term clinical course of immunotactoid glomerulopathy complicated with diffuse large B-cell lymphoma
    Haruka Takahashi
    Takashi Sano
    Sayumi Kawamura
    Keiko Sano
    Ryoma Miyasaka
    Takuya Yamazaki
    Mayuko Sakakibara
    Tetsuya Abe
    Keiko Hashimoto
    Miki Nagaoka
    Mariko Kamata
    Shokichi Naito
    Togo Aoyama
    Rika Moriya
    Yasuo Takeuchi
    CEN Case Reports, 2022, 11 : 184 - 190
  • [43] PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation
    Elbaek, Mette Vestergaard
    Pedersen, Mette Olgod
    Breinholt, Marie Fredslund
    Reddy, Anupama
    Love, Cassandra
    Clasen-Linde, Erik
    Knudsen, Helle
    Nielsen, Signe Ledou
    Gang, Anne Ortved
    Hogdall, Estrid
    Dave, Sandeep
    Norgaard, Peter
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (04) : 375 - 382
  • [44] Non Double-Hit Diffuse Large B Cell Lymphoma Treated with R-CHOP Has Excellent Overall Survival If Interim Scan Shows Partial or Complete Response
    Murphy, Philip
    Glavey, Siobhan
    Breathnach, Oscar
    Murphy, Philip W.
    Grogan, Liam
    Morris, Patrick
    Quinn, John
    BLOOD, 2020, 136
  • [45] PD-L1 Expression Is Low in Large B-Cell Lymphoma with MYC or Double-Hit Translocation
    Elbaek, Mette Vestergaard
    Pedersen, Mette O.
    Breinholt, Marie Fredslund
    Reddy, Anupama
    Love, Cassandra
    Clasen-Linde, Erik
    Knudsen, Helle
    Nielsen, Signe Ledou
    Gang, Anne Ortved
    Hogdall, Estrid
    Dave, Sandeep
    Norgaard, Peter H.
    BLOOD, 2018, 132
  • [46] Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma
    Yang, Yulu
    Chen, Rui
    Gong, Yi
    Yang, Weihu
    Li, Ke
    Fan, Wuzhe
    Gou, Shuangquan
    Gao, Pengfei
    He, Tingting
    Cai, Kaiyong
    BIOMATERIALS, 2022, 287
  • [47] Complete remission of a diffuse large B-cell lymphoma in a young patient, with severe tuberous sclerosis, treated with metronomic chemotherapy and ibrutinib: a case report.
    Banchi, Marta
    Lanzolla, Tiziana
    Di Napoli, Arianna
    Bandini, Arianna
    Bocci, Guido
    Cox, Maria Christina
    CHEMOTHERAPY, 2024, 69 (01) : 40 - 44
  • [48] Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
    Bari, Alessia
    Gerardi, Chiara
    Allocati, Eleonora
    Puzzovivo, Agata
    De Sanctis, Vitaliana
    Tucci, Alessandra
    Balzarotti, Monica
    Franceschetti, Silvia
    Merli, Francesco
    Guarini, Attilio
    Gini, Guido
    Minoia, Carla
    CANCERS, 2022, 14 (23)
  • [49] Long Term Outcomes of Allogeneic Transplant in Diffuse Large B-Cell Lymphoma
    Modi, Dipenkumar
    Kim, Seongho
    Surapaneni, Malini
    Deol, Abhinav
    Alavi, Asif
    Ayash, Lois
    Ratanatharathorn, Voravit
    Uberti, Joseph P.
    BLOOD, 2018, 132
  • [50] Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly/FRAIL Patients, with Diffuse Large B-Cell Lymphoma
    Cox, M. Christina
    Pelliccia, Sabrina
    Orlandi, Paola
    Di Napoli, Arianna
    Musuraca, Gerardo
    Patti, Caterina
    Bianchi, Maria Paola
    Caridi, Matteo
    Banchi, Marta
    Battistini, Roberta
    Lanzolla, Tiziana
    Tafuri, Agostino
    Bocci, Guido
    BLOOD, 2022, 140 : 3796 - 3797